ALT – Altimmune Inc
[iframe https://s.tradingview.com/embed-widget/symbol-info/?locale=in&symbol=ALT
#%7B%22symbol%22%3A%22A%22%2C%22width%22%3A%22100%25%22%2C%22colorTheme%22%3A%22light%22%2C%22isTransparent%22%3Atrue%2C%22height%22%3A203%2C%22utm_source%22%3A%22themarketstracker.com%22%2C%22utm_medium%22%3A%22widget_new%22%2C%22utm_campaign%22%3A%22symbol-info%22%7D 900 250 ]
ALT — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
26.27
Margin Of Safety %
Put/Call OI Ratio
0.08
EPS Next Q Diff
0.05
EPS Last/This Y
0.43
EPS This/Next Y
-0.12
Price
3.07
Target Price
17.22
Analyst Recom
1.3
Performance Q
1.32
Upside
-496.8%
Beta
0.17
Ticker: ALT
20 items
«
‹
of 1
›
»
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-07-13 | ALT | 3 | 0.06 | 0.04 | 160678 |
| 2026-07-14 | ALT | 2.93 | 0.06 | 0.06 | 162766 |
| 2026-07-15 | ALT | 2.98 | 0.06 | 0.08 | 163903 |
| 2026-07-16 | ALT | 2.85 | 0.06 | 0.25 | 164633 |
| 2026-07-17 | ALT | 2.87 | 0.06 | 0.02 | 165353 |
| 2026-07-20 | ALT | 2.8 | 0.06 | 0.02 | 158555 |
| 2026-07-21 | ALT | 2.82 | 0.06 | 0.17 | 162019 |
| 2026-07-22 | ALT | 2.82 | 0.06 | 0.10 | 162454 |
| 2026-07-23 | ALT | 2.84 | 0.06 | 0.04 | 162945 |
| 2026-07-24 | ALT | 2.76 | 0.06 | 0.19 | 163274 |
| 2026-07-27 | ALT | 2.96 | 0.06 | 0.04 | 161037 |
| 2026-07-28 | ALT | 3 | 0.06 | 0.09 | 163331 |
| 2026-07-29 | ALT | 2.93 | 0.06 | 1.11 | 169809 |
| 2026-07-30 | ALT | 2.97 | 0.07 | 0.38 | 172569 |
| 2026-07-31 | ALT | 2.85 | 0.08 | 0.42 | 175728 |
| 2026-08-03 | ALT | 2.99 | 0.08 | 0.03 | 173060 |
| 2026-08-04 | ALT | 3.07 | 0.08 | 0.05 | 175371 |
| 2026-08-05 | ALT | 3.04 | 0.08 | 0.07 | 176526 |
| 2026-08-06 | ALT | 3.01 | 0.08 | 0.13 | 177017 |
| 2026-08-07 | ALT | 3.07 | 0.08 | 0.14 | 177975 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
20 items
«
‹
Current Page1 of 1
›
»
20 items
«
‹
of 1
›
»
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-07-13 | ALT | 3.00 | 41.8 | - | -0.71 |
| 2026-07-14 | ALT | 2.93 | 41.8 | - | -0.71 |
| 2026-07-15 | ALT | 2.98 | 41.8 | - | -0.71 |
| 2026-07-16 | ALT | 2.84 | 41.8 | - | -0.71 |
| 2026-07-17 | ALT | 2.87 | 41.8 | - | -0.71 |
| 2026-07-20 | ALT | 2.80 | 41.8 | - | -0.71 |
| 2026-07-21 | ALT | 2.81 | 41.8 | - | -0.71 |
| 2026-07-22 | ALT | 2.82 | 41.8 | - | -0.71 |
| 2026-07-23 | ALT | 2.84 | 41.8 | - | -0.71 |
| 2026-07-24 | ALT | 2.76 | 41.8 | - | -0.71 |
| 2026-07-27 | ALT | 2.97 | 41.8 | - | -0.71 |
| 2026-07-28 | ALT | 3.00 | 41.8 | - | -0.67 |
| 2026-07-29 | ALT | 2.93 | 41.8 | - | -0.67 |
| 2026-07-30 | ALT | 2.97 | 41.8 | - | -0.67 |
| 2026-07-31 | ALT | 2.85 | 53.7 | - | -0.57 |
| 2026-08-03 | ALT | 3.00 | 53.7 | - | -0.57 |
| 2026-08-04 | ALT | 3.00 | 53.7 | - | -0.57 |
| 2026-08-05 | ALT | 3.04 | 53.7 | - | -0.57 |
| 2026-08-06 | ALT | 3.01 | 53.7 | - | -0.57 |
| 2026-08-07 | ALT | 3.07 | 53.7 | - | -0.57 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
20 items
«
‹
Current Page1 of 1
›
»
20 items
«
‹
of 1
›
»
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-07-13 | ALT | 0.55 | 16.52 | 25.93 |
| 2026-07-14 | ALT | 0.55 | 16.52 | 25.93 |
| 2026-07-15 | ALT | 0.55 | 16.52 | 25.93 |
| 2026-07-16 | ALT | 0.55 | 16.52 | 25.93 |
| 2026-07-17 | ALT | 0.55 | 16.52 | 25.93 |
| 2026-07-20 | ALT | 0.55 | 16.46 | 25.93 |
| 2026-07-21 | ALT | 0.55 | 16.46 | 25.93 |
| 2026-07-22 | ALT | 0.55 | 16.46 | 25.93 |
| 2026-07-23 | ALT | 0.55 | 16.46 | 25.93 |
| 2026-07-24 | ALT | 0.55 | 16.46 | 25.93 |
| 2026-07-27 | ALT | 0.55 | 16.47 | 26.27 |
| 2026-07-28 | ALT | 0.55 | 16.47 | 26.27 |
| 2026-07-29 | ALT | 0.55 | 16.47 | 26.27 |
| 2026-07-30 | ALT | 0.55 | 16.47 | 26.27 |
| 2026-07-31 | ALT | 0.55 | 16.47 | 26.27 |
| 2026-08-03 | ALT | 0.55 | 16.64 | 26.27 |
| 2026-08-04 | ALT | 0.55 | 16.64 | 26.27 |
| 2026-08-05 | ALT | 0.55 | 16.64 | 26.27 |
| 2026-08-06 | ALT | 0.55 | 16.64 | 26.27 |
| 2026-08-07 | ALT | 0.55 | 16.64 | 26.27 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
20 items
«
‹
Current Page1 of 1
›
»
[iframe https://widget.finnhub.io/widgets/historical-eps?symbol=ALT
589 360 ]
Last Quarter Act. EPS
-0.18
Avg. EPS Est. Current Quarter
-0.13
Avg. EPS Est. Next Quarter
-0.13
Insider Transactions
0.55
Institutional Transactions
16.64
Beta
0.17
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
29
Growth Score
23
Sentiment Score
78
Actual DrawDown %
86.9
Max Drawdown 5-Year %
-90.5
Target Price
17.22
P/E
Forward P/E
PEG
P/S
14974.58
P/B
1.41
P/Free Cash Flow
EPS
-0.94
Average EPS Est. Cur. Y
-0.57
EPS Next Y. (Est.)
-0.69
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-253002.78
Relative Volume
1.13
Return on Equity vs Sector %
-59.4
Return on Equity vs Industry %
-43.3
EPS 1 7Days Diff
0.1
EPS 1 30Days Diff
0.14
EBIT Estimation
[iframe https://widget.finnhub.io/widgets/recommendation?symbol=ALT
589 450 ]
[iframe https://widget.finnhub.io/widgets/eps-estimate?symbol=ALT
589 450 ]
◆
ALT
Healthcare
$3.08
📉
Swing / Pullback
Buy the dip on strong trends
WEAK
Trend
6/20
Pullback
12/25
Volume
4/15
Valuation
12/20
TP/AR
2/10
Options
8/10
RSI
57.2
Range 1M
51.8%
Sup Dist
3.9%
🚀
N/A
Momentum Growth
Ride accelerating trends
WEAK
Momentum
5/25
Growth
18/30
Estimates
0/20
Inst/Vol
8/15
Options
8/10
EPS Yr
39.7%
EPS NY
-8.9%
52W%
12.4%
💎
N/A
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+459.1% upside
Quality
2/30
Valuation
16/30
Growth
13/25
Stability
7/10
LT Trend
3/5
Upside
+459.1%
Quality
29
Click a card to see score breakdown
Full Analysis →
ALT — P/E HistoricalBiotechnology
Sector: Healthcare
Industry: Biotechnology
Employees: 57
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
[News_ALT
_Stock]
stock quote shares ALT – Altimmune Inc Stock Price stock today
news today ALT – Altimmune Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch ALT – Altimmune Inc yahoo finance google finance
stock history ALT – Altimmune Inc invest stock market
stock prices ALT
premarket after hours
ticker ALT
fair value insiders trading